Table 2.
EP-9 Results of In2it and DCA Vantage (DCA V.) with Two Different Lot Numbers
| Deming regression lines | Lot number A | 95% CI of 6% HbA1c | 95% CI of 9% HbA1c | Lot number B | 95% CI of 6% HbA1c | 95% CI of 9% HbA1c |
|---|---|---|---|---|---|---|
| Primus Ultra2 (X) vs In2it (Y) | Y = 0.951X + 0.257 | Y = 0.965X + 0.239 | ||||
| Standard error of estimates | 0.514 | 5.77–6.15a | 8.53–8.99a | 0.255 | 5.95–6.11 | 8.86–8.99 |
| R | 0.96 | (0.38) | (0.46) | 0.99 | (0.15) | (0.13) |
| Tina-quant (X) vs In2it (Y) | Y = 0.928X + 0.350 | Y = 0.930X + 0.454 | ||||
| Standard error of estimates | 0.561 | 5.70–6.07a | 8.50–9.02a | 0.300 | 5.94–6.12 | 8.75–8.89 |
| R | 0.95 | (0.37) | (0.52) | 0.99 | (0.18) | (0.14) |
| Tosoh G7 (X) vs In2it (Y) | Y = 0.926X + 0.22 | Y = 0.980X + 0.050 | ||||
| Standard error of estimates | 0.59 | 5.58–5.94a | 8.41–8.90a | 0.308 | 5.83–6.03 | 8.79–8.94 |
| R | 0.95 | (0.36) | (0.49) | 0.99 | (0.20) | (0.15) |
| Primus Ultra2 (X) vs DCA V. (Y) | Y = 0.919X + 0.576 | Y = 1.038X – 0.017 | ||||
| Standard error of estimates | 0.310 | 5.99–6.19 | 8.77–8.93 | 0.278 | 6.16–6.33 | 9.29–9.42 |
| R | 0.98 | (0.20) | (0.16) | 0.99 | (0.17) | (0.13) |
| Tina-quant (X) vs DCA V. (Y) | Y = 0.921X + 0.482 | Y = 1.003X + 0.219 | ||||
| Standard error of estimates | 0.26 | 5.97–6.05b | 8.68–8.87b | 0.249 | 6.16–6.31 | 9.19–9.31 |
| R | 0.99 | (0.08) | (0.19) | 0.99 | (0.15) | (0.12) |
| Tosoh G7 (X) vs DCA V. (Y) | Y = 0.975X – 0.03 | Y = 1.057X – 0.218 | ||||
| Standard error of estimates | 0.42 | 5.74–5.89b | 8.67–8.81b | 0.258 | 6.07–6.19b | 9.16–9.44b |
| R | 0.98 | (0.15) | (0.14) | 0.99 | (0.12) | (0.28) |
a
Calculated by partitioned biases.
b
Calculated by partitioned residuals.